ClinicalTrials.gg
Active, not recruitingNCT06584383Updated May 6, 2026

A Prospective, Randomized, Controlled Trial to Test Safety and Effectiveness of Unilateral Exablate MR-guided Focused Ultrasound Subthalamotomy in Patients With Early-Stage Parkinson's Disease

An interventional study of Exablate MRgFUS subthalamotomy and Best Medical Treatment in Parkinson Disease, sponsored by InSightec. Active, not recruiting at 4 sites in 3 countries. Open to participants aged 30 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by InSightec · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
67
Allocation
Randomized
Ages
30 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 19 studies in Parkinson Disease by InSightec — 3 open to participants now, 9 under way, none of them phase 3. Parkinson Disease · InSightec.

Enrollment
3rd of 16
67 · median 20
Started
2024
the only one that year
No phase
16 of 19
1 open now
Registered
18th of 19
by date

Among the 19 studies in Parkinson Disease by InSightec, this one is the 3rd largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2024, is one of 16 with no phase, and was the 18th registered.

Parkinson Disease

4,581 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

3 of the 19 studies in Parkinson Disease by InSightec are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 313 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 30 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Parkinson Disease by InSightec, or all of them as a file.
02

Study summary

This prospective, randomized, multicenter study aims to evaluate in Early-Stage Parkinson's Disease (ESPD) patients the safety and effectiveness of treatment with Exablate MRgFUS subthalamotomy vs best medical treatment.

Read the detailed description

This is a prospective, randomized (ratio 2:1), multicenter study to evaluate in Early-Stage Parkinson's Disease (ESPD) patients the safety and effectiveness of treatment with Exablate MRgFUS subthalamotomy vs best medical treatment. Patients assigned to the treatment arm will receive unilateral Exablate MRgFUS subthalamotomy. Patients assigned to control group will receive best medical treatment.

03

Conditions studied

  • Parkinson Disease

Browse trials for

Keywords

  • Exablate
  • MRgFUS
  • Subthalamotomy
04

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women; age 30 to 65 years old
  • Subjects who are able and willing to give consent and able to attend all study visits. - Subjects with a diagnosis of PD according to the modified clinical criteria by the Movement Disorders Society, for less than 5 years and more than 12 months.
  • Off-medication MDS-UPDRS part III of the most affected body side ≥ 10
  • Motor signs predominantly present in one body side: Asymmetry index (MDS-UPDRS III of the most affected side/MDS-UPDRS III of the least effected side) ≥ 2.
  • Patients should have a stable pharmacological regime for the last 4-weeks prior to baseline evaluation.
  • Topographic coordinates of the subthalamic nucleus are localizable on MRI so that it can be targeted by the Exablate device.
  • Skull density ratio (SDR) score of 0.40 or higher*. The SDR is a determinant factor for the suitability to MRgFUS ablation. SDR is a ratio of ultrasound energy penetration through the skull. The SDR threshold for using Exablate 4000 is established at 0.4 with patients having SDR below that value considered unsuitable candidates.
  • Able to communicate sensations during the Exablate MRgFUS treatment.

Exclusion criteria

Exclusion Criteria:

  • MDS-UPDRS part III OFF medications > 32 in the off state and/or Hoehn and Yahr state ON medication greater than 2.
  • Significative evidence (by clinical history) of having developed features indicative of PD motor onset 2 or more years prior to formal diagnosis.
  • Presence of levodopa-induced dyskinesia and/or motor fluctuations as noted by a score > 1 on questions 4.2 or 4.4 of the MDS-UPDRS, that assess disability resulting from motor complications.
  • Levodopa daily dose higher than 500mg or 750 levodopa-equivalents daily.
  • Presence of any symptoms or signs suggesting other central neurodegenerative disease such as multisystem atrophy, progressive supranuclear palsy, cortico-basal syndrome, dementia with Lewy bodies, and Alzheimer's disease.
  • Any suspicion that parkinsonian symptoms are a side effect attributable to intake of neuroleptic or other medications.
  • Subjects who have had deep brain stimulation or a prior stereotactic ablation for the treatment of movement disorders.
  • Presence of significant cognitive impairment measured by standard of care method at the center.
  • Patients with clinically relevant co-morbidity such as severe hypertension, diabetes, cardiac, metabolic, and psychiatric conditions
  • Other exclusion criteria for the Exablate system.
  • Subjects with significant depression as determined following a comprehensive assessment by a neuropsychologist. Significant depression is being defined quantitatively as a score of greater than 14 on the Beck Depression Inventory.
  • Legal incapacity or limited legal capacity as determined by the neuropsychologist.
  • Subjects exhibiting any behavior(s) consistent with ethanol or substance abuse as defined by the criteria outlined in the as manifested by one (or more) of the following occurring within the preceding 12-month period:

    • Recurrent substance use resulting in a failure to fulfill major role obligations at work, school, or home (such as repeated absences or poor work performance related to substance use; substance-related absences, suspensions, or expulsions from school; or neglect of children or household).
    • Recurrent substance use in situations in which it is physically hazardous (such as driving an automobile or operating a machine when impaired by substance use).
    • Recurrent substance-related legal problems (such as arrests for substance related disorderly conduct).
    • Continued substance use despite having persistent or recurrent social or interpersonal problems caused or exacerbated by the effects of the substance (for example, arguments with spouse about consequences of intoxication and physical fights).
  • Subjects with unstable cardiac status including:

    • Unstable angina pectoris on medication
    • Subjects with documented myocardial infarction within six months of protocol entry
    • Significant congestive heart failure defined with \<40.
    • Subjects with unstable ventricular arrhythmias
    • Subjects with atrial arrhythmias that are not rate controlled.
    • Severe hypertension (diastolic BP >100 on medication).
  • History of or current medical condition resulting in abnormal bleeding and/or coagulopathy.
  • Receiving anticoagulant (e.g., warfarin) or antiplatelet (e.g., aspirin) therapy within one week of focused ultrasound procedure or drugs known to increase risk or hemorrhage (e.g., Avastin) within one month of focused ultrasound procedure.
  • Subjects with risk factors for intraoperative or postoperative bleeding as indicated by: count less than 100,000 per cubic millimeter, a documented clinical coagulopathy, or coagulation studies exceeding the institution's laboratory standard.
  • Patient with severely impaired renal function with estimated \<30mL/min/1.73m2 (or per local standards should that be more restrictive) and/or who is on dialysis.
  • Subjects with standard for MR imaging such as non-MRI compatible implanted metallic devices including cardiac pacemakers, size limitations, etc.
  • Significant claustrophobia that cannot be managed with mild medication.
  • Subject who weighs more than the upper weight limit of the MR table and who cannot fit into the MR scanner.
  • Subjects who are not able or willing to tolerate the required prolonged stationary supine position during treatment.
  • History of intracranial hemorrhage.
  • History of multiple strokes, or a stroke within past 6 months.
  • Subjects with a history of seizures within the past year.
  • Subjects with malignant brain tumors.
  • Subjects with intracranial aneurysms requiring treatment or arterial venous malformations (AVMs) requiring treatment.
  • Any illness that in the investigator's opinion preclude participation in this study.
  • Subjects unable to communicate with the investigator and staff.
  • Pregnancy or lactation.
  • Patients without clinically relevant parkinsonism in the off- state as evaluated by two examining neurologists (or MDS- UPDRS III in the most affected side \<10).
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
67 participants (actual)

Study arms

  • Experimental
    Exablate Arm

    Subjects will receive Exablate MRgFUS subthalamotomy

    Procedure: Exablate MRgFUS subthalamotomy

  • Active comparator
    Control Arm

    Subjects will receive best medical treatment. If patients from the control arm undergo the unilateral Exablate MRgFUS subthalamotomy between month 12 to 36, they will be exiting the study.

    Procedure: Exablate MRgFUS subthalamotomy · Drug: Best Medical Treatment

  • Active comparator
    Reference Arm

    Patients fulfilling all inclusion/exclusion criteria except for the SDR requirements (and so anatomically not able to undergo MRgFUS subthalamotomy) will be offered the option to receive best medical treatment and will be formally followed as a reference comparator for up to 3 years.

    Drug: Best Medical Treatment

Interventions

  • ProcedureExablate MRgFUS subthalamotomy

    Exablate MRgFUS subthalamotomy for Parkinson's Disease

  • DrugBest Medical Treatment

    Subjects will be managed according to conventional therapeutic guidelines (i.e., best medical treatment) for Parkinson's Disease

06

What researchers measure

Primary outcomes

  1. MDS-UPDRS Part III OFF Medication

    Between-group difference (Exablate and control) in the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III at 12 months in the off-medication state.

    Time frame: 12 Months

Secondary outcomes

  1. PD-specific spatial covariance patterns (PDRP or PD related metabolic pattern) with brain 18F-fluorodeoxyglucose- Positron emission tomography

    The metabolic pattern will be quantified to obtain a PDRP expression scores at baseline, 12-month and to compare disease evolution between groups.

    Time frame: 12 Months

  2. MDS-UPDRS III OFF-med video-based evaluation

    Between group comparison (Exablate and control) through month 12 and within group comparison vs baseline month 12 in MDS-UPDRS III OFF-med video-based evaluation by a blinded movement disorders neurologist (only at baseline and 12 months).

    Time frame: 12 Months

  3. MDS-UPDRS I, II, III (ON and OFF meds) and UPDRS IV

    Between group (Exablate and control) comparison through month 12 and within and between group (Exablate and comparator) comparison vs baseline, month 12 to 36 in MDS-UPDRS I, II, III (ON and OFF meds) and UPDRS IV.

    Time frame: 12 Months, 24 Months, 36 Months

  4. MDS Unified Dyskinesia Rating Scale

    Between group (Exablate and control) comparison through month 12 and within and between group (Exablate and comparator) comparison vs baseline, month 12 to 36 in MDS Unified Dyskinesia Rating Scale.

    Time frame: 12 Months, 24 Months, 36 Months

  5. Quality of life assessment (PDQ39)

    Between group (Exablate and control) comparison through month 12 and within and between group (Exablate and comparator) comparison vs baseline, month 12 to 36 in Quality-of-life assessment (PDQ39).

    Time frame: 12 Months, 24 Months, 36 Months

  6. Levodopa equivalent dose change usage (milligrams)

    Between group (Exablate and control) comparison through month 12 and within and between group (Exablate and comparator) comparison vs baseline, month 12 to 36 in Levodopa equivalent dose usage (milligrams).

    Time frame: 12 Months, 24 Months, 36 Months

  7. MDS-Non motor rating scale

    Between group (Exablate and control) comparison through month 12 and within and between group (Exablate and comparator) comparison vs baseline, month 12 to 36 in MDS-Non motor rating scale.

    Time frame: 12 Months, 24 Months, 36 Months

  8. Patient Global Impression of Change (PGIC)

    Between group (Exablate and control) comparison through month 12 and within and between group (Exablate and comparator) comparison vs baseline, month 12 to 36 in Patient Global Impression of Change (PGIC).

    Time frame: 12 Months, 24 Months, 36 Months

  9. Clinician Global Impression of Change (CGIC)

    Between group (Exablate and control) comparison through month 12 and within and between group (Exablate and comparator) comparison vs baseline, month 12 to 36 in Clinician Global Impression of Change (CGIC).

    Time frame: 12 Months, 24 Months, 36 Months

Other outcomes

  1. Safety: Incidence and frequency of adverse events related to the treatment.

    Incidence and frequency of adverse events related to the treatment. The investigator will capture any untoward events related to the treatment in the case report forms along with severity, duration, and resolution, and whether the event is considered serious. The severity of adverse events will be categorized according to the definition of adverse events from the International Organization for Standardization (ISO).

    Time frame: 36 Months

  2. Exploratory assessment: F- Dopa PET assessment

    F- Dopa PET assessment will evaluate difference in the progression of striatal dopaminergic denervation.

    Time frame: 12 Months, 36 Months

  3. Exploratory assessment: Time to Parkinson's Disease Progression

    PD progression will also be defined by comparing between-group Kaplan-Meier curves of subjects exceeding the worsening thresholds of specific clinical scales

    Time frame: 12 Months, 24 Months, 36 Months

07

Study locations

4 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Sep 2027, 37 months after the start.

Of 76 industry-sponsored interventional studies with no phase under Parkinson Disease, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 43. This study's planned 37 months is above that.

Counting every sponsor, half of 1,371 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 30, 2024
First posted
Sep 4, 2024
StartActual
Aug 1, 2024
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2029
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06584383
Lead sponsor
InSightec
Responsible party
Sponsor
First posted
Sep 4, 2024
Start date
Aug 1, 2024
Primary completion
Sep 2027 (estimated)
Completion
Sep 2029 (estimated)
Last update
May 6, 2026

Study contacts

José Obeso, MD, PhD
principal investigator · HM CINAC- Hospital Universitario HM Puerta del Sur
Raúl Martínez-Fernández, MD, PhD
principal investigator · HM CINAC- Hospital Universitario HM Puerta del Sur

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion